TheraRadar

Pharma Intelligence, Simplified

← Back
Data updated: Mar 10, 2026

SOLOPAK

CardiovascularDermatologyNeurology
Pharma

SOLOPAK is a pharmaceutical company focused on Cardiovascular, Dermatology, Neurology.

-
Since
16
Drugs
-
Trials
120
Approved (2yr)

Key Drugs

No active drugs

Recent Activity

HEPARIN SODIUM 2026-02-20
Labeling
HEPARIN SODIUM 2026-02-20
Labeling
PROPRANOLOL HYDROCHLORIDE 2026-01-27
HALOPERIDOL 2025-12-18
HYDROXYZINE HYDROCHLORIDE 2025-12-16
VERAPAMIL HYDROCHLORIDE 2025-11-24
VERAPAMIL HYDROCHLORIDE 2025-11-13
TRIMETHOBENZAMIDE HYDROCHLORIDE 2025-10-16
HEPARIN SODIUM 2025-09-24
Labeling
VERAPAMIL HYDROCHLORIDE 2025-09-19
Labeling
SEC Filings Pro
Loading...

Therapeutic Focus

Score weights: Approved drugs ×3, Phase 3 ×2, Phase 2 ×1, Phase 1 ×0.5

Cardiovascular 50%
2 drugs
Dermatology 25%
1 drugs
Neurology 25%
1 drugs

Pipeline Strength Pro

Loading...

Competitors Pro

LEDERLE big-pharma
Cardiovascular, Neurology, Dermatology
PAI HOLDINGS PHARM big-pharma
Dermatology, Neurology, Cardiovascular
Baxter specialty
Cardiovascular, Dermatology
OTSUKA big-pharma
Neurology, Dermatology, Cardiovascular
ADVANZ PHARMA big-pharma
Neurology, Cardiovascular, Dermatology